|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-8-3
|
|
pubmed:abstractText |
Increased concentrations of tumor necrosis factor (TNF), a potent proinflammatory cytokine, can be shown in the mucosa of patients with active Crohn's disease. Neutralization of TNF has been shown to decrease recruitment of inflammatory cells and granuloma formation in several animal models. The aim of this study was to investigate the safety and potential efficacy of an anti-TNF monoclonal antibody in the treatment of active Crohn's disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
129-35
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7797011-Adult,
pubmed-meshheading:7797011-Analysis of Variance,
pubmed-meshheading:7797011-Animals,
pubmed-meshheading:7797011-Antibodies, Monoclonal,
pubmed-meshheading:7797011-Blood Sedimentation,
pubmed-meshheading:7797011-C-Reactive Protein,
pubmed-meshheading:7797011-Cloning, Molecular,
pubmed-meshheading:7797011-Colon,
pubmed-meshheading:7797011-Crohn Disease,
pubmed-meshheading:7797011-Female,
pubmed-meshheading:7797011-Humans,
pubmed-meshheading:7797011-Interleukin-6,
pubmed-meshheading:7797011-Male,
pubmed-meshheading:7797011-Mice,
pubmed-meshheading:7797011-Middle Aged,
pubmed-meshheading:7797011-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:7797011-Recombinant Fusion Proteins,
pubmed-meshheading:7797011-Recurrence,
pubmed-meshheading:7797011-Remission Induction,
pubmed-meshheading:7797011-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
|
|
pubmed:affiliation |
Department of Hepatogastroenterology, Academic Medical Center, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
